Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the large-scale production environment. These new lines are the first of several planned silkworm strains in our hybridization program, which are explicitly designed to increase robustness and cocoon size.
These strains blend the mechanical performance of the Company’s original Dragon Silk with the size and robustness of native production silkworm strains. The Company engineered these strains as part of its development program to bring needed increased resiliency to the large-scale production environment.
Best practices employed by the most advanced silkworm egg production facilities include utilizing a multi-line cross-mating protocol to generate increased robustness. The result of first-generation cross-matings yield larger cocoons and more resilient silkworm offspring. As these increased performance attributes only last one generation, it is vital that central silkworm egg production operations sustain each of these separate lines in order to create successive generations of hybrid crosses.
Kraig Labs begins its transition to multi-line cross-mating with these two new hybrids. Once established at the production facilities, the Company will start cross-matings to produce our first two-line production hybrids. Kraig Labs believes this will strengthen its production operations, increase silkworm resiliency, and significantly improve environmental tolerance.
As part of the Company’s ongoing development efforts to commercialize spider silk production, it is also developing a four-line hybrid-cross program that should further improve yields. This program is under development at the Company’s R&D headquarters located in the USA and is planned to begin rollout in stages later this year following the successful implementation of the two-line hybrid-cross model.
“Work with our production partner in Vietnam has accelerated the identification of challenges and opportunities in scaling up production to metric tonnage levels,” said Company COO Jon Rice. “We are very pleased to announce the delivery of these new hybrid lines and we are excited about our ongoing development of the four-line hybrid-cross. The implementation of the four-line hybrid program is designed to deliver significant improvements in production capacity and yield.”
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “should,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
